I used to swallow down a tablet of Zantac, 150 mgs of Ranitidine, when heartburn struck, until I read this:
“A popular heartburn drug has been withdrawn from sale after it was found to carry a cancer-causing substance. Zantac – sold over the counter - is among eight types of the heartburn drug ranitidine that have been recalled from pharmacies, supermarkets, online stores and other retail outlets. The products were contaminated with an impurity called N nitrosodimethylamine (NDMA). As well as heartburn, the ranitidine products can be used to treat stomach acid, reflux and ulcers. The move came after concerns long-term exposure to NDMA was found to increase a person's chances of developing cancer. The Therapeutic Goods Administration (TGA) is advising people to consider alternative medicines.’
Looks like I am back to proton pump inhibitors, which have been linked to heart attacks:
Background and Aims
Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results suggest that this risk might extend to subjects without any prior history of cardiovascular disease. We explore this potential risk in the general population via data-mining approaches.
Using a novel approach for mining clinical data for pharmacovigilance, we queried over 16 million clinical documents on 2.9 million individuals to examine whether PPI usage was associated with cardiovascular risk in the general population.
In multiple data sources, we found gastroesophageal reflux disease (GERD) patients exposed to PPIs to have a 1.16 fold increased association (95% CI 1.09–1.24) with myocardial infarction (MI). Survival analysis in a prospective cohort found a two-fold (HR = 2.00; 95% CI 1.07–3.78; P = 0.031) increase in association with cardiovascular mortality. We found that this association exists regardless of clopidogrel use. We also found that H2 blockers, an alternate treatment for GERD, were not associated with increased cardiovascular risk; had they been in place, such pharmacovigilance algorithms could have flagged this risk as early as the year 2000.
Consistent with our pre-clinical findings that PPIs may adversely impact vascular function, our data-mining study supports the association of PPI exposure with risk for MI in the general population. These data provide an example of how a combination of experimental studies and data-mining approaches can be applied to prioritize drug safety signals for further investigation.”
Better yet I will continue to refine my diet to control the gastro and acid reflux: